Elevated expression of SHIP2 correlates with poor prognosis in non-small cell lung cancer

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 10, 2013, Pages 2185-2191

  Fu, Maoying ^a   Fan, Weifei ^b   Pu, Xiaolin ^b   Ni, Huihui ^a   Zhang, Wei ^a   Chang, Feng ^a   Gong, Li ^a   Xiong, Lin ^c   Wang, Jun ^b   Gu, Xuefeng ^a  

^a KUNSHAN FIRST PEOPLE S HOSPITAL AFFILIATED TO JIANGSU UNIVERSITY   (China)

^b Jiangsu Province Hospital   (China)

^c THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Immunohistochemistry; NSCLC; Prognosis; qPCR; SHIP2

Indexed keywords

INPPL1 PROTEIN, HUMAN; PHOSPHATASE;

ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NSCLC; PATHOLOGY; PROGNOSIS; QPCR; SHIP2; SURVIVAL RATE; VERY ELDERLY;

IMMUNOHISTOCHEMISTRY; NSCLC; PROGNOSIS; QPCR; SHIP2;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORIC MONOESTER HYDROLASES; PROGNOSIS; SURVIVAL RATE;

EID: 84885413881     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Kawakami M, Morita S, Sunohara M, Amano Y, Ishikawa R, Watanabe K, Hamano E, Ohishi N, Nakajima J, Yatomi Y, Nagase T, Fukayama M, Takai D. FER overexpression is associated with poor postoperative prognosis and cancer-cell survival in non-small cell lung cancer. Int J Clin Exp Pathol 2013; 6: 598-612.
2. Sloan JA. Metrics to assess quality of life after management of early-stage lung cancer. Cancer J 2011; 17: 63-67.
3. Wen C, Dehnel T. China wrestles with lung cancer. Lancet Oncol 2011; 12: 15.
4. Esposito L, Conti D, Ailavajhala R, Khalil N, Giordano A. Lung cancer: are we up to the challenge? Curr Genomic 2010; 11: 513-518.
5. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83: 584-594.
6. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
7. Feng J, Zhang X, Zhu H, Wang X, Ni S, Huang J. FoxQ1 overexpression influences poor prognosis in non-small cell lung cancer, associates with the phenomenon of EMT. PLoS One 2012; 7: e39937.
8. Feng J, Zhang X, Zhu H, Wang X, Ni S, Huang J. High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer. Am J Clin Pathol 2012; 138: 230-235.
9. Pesesse X, Deleu S, De Smedt F, Drayer L, Erneux C. Identification of a second SH2-domain-containing protein closely related to the phosphatidylinositol polyphosphate 5-phosphatase SHIP. Biochem Biophys Res Commun 1997; 239: 697-700.
10. Dobbin ZC, Landen CN. The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer. Int J Mol Sci 2013; 14: 8213-8227.
11. Provenzano A, Kurian S, Abraham J. Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways. Expert Rev Anticancer Ther 2013; 13: 143-147.
12. Wang G, Wang F, Ding W, Wang J, Jing R, Li H, Wang X, Wang Y, Ju S, Wang H. APRIL induces tumorigenesis and metastasis of colorectal cancer cells via activation of the PI3K/Akt pathway. PLoS One 2013; 8: e55298.
13. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
14. Prasad NK, Topping RS, Decker SJ. SH2-containing inositol 5'-phosphatase SHIP2 associates with the p130(Cas) adapter protein and regulates cellular adhesion and spreading. Mol Cell Biol 2001; 21: 1416-1428.
15. Prasad NK, Decker SJ. SH2-containing 5'-inositol phosphatase, SHIP2, regulates cytoskeleton organization and ligand-dependent down-regulation of the epidermal growth factor receptor. J Biol Chem 2005; 280: 13129-13136.
16. Prasad NK, Tandon M, Handa A, Moore GE, Babbs CF, Snyder PW, Bose S. High expression of obesity-linked phosphatase SHIP2 in invasive breast cancer correlates with reduced disease-free survival. Tumour Biol 2008; 29: 330-341.
17. Zhou X, Liu Y, Tan G. Prognostic value of elevated SHIP2 expression in laryngeal squamous cell carcinoma. Arch Med Res 2011; 42: 589-595.
18. Mao Y, Zhang DW, Lin H, Xiong L, Liu Y, Li QD, Ma J, Cao Q, Chen RJ, Zhu J, Feng ZQ. Alpha B-crystallin is a new prognostic marker for laryngeal squamous cell carcinoma. J Exp Clin Cancer Res 2012; 31: 101.
19. Mao Y, Zhang DW, Wen J, Cao Q, Chen RJ, Zhu J, Feng ZQ. A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor. Int J Mol Sci 2012; 13: 2208-2218.
20. Han L, Jiang B, Wu H, Wang X, Tang X, Huang J, Zhu J. High expression of CXCR2 is associated with tumorigenesis, progression, and prognosis of laryngeal squamous cell carcinoma. Med Oncol 2012; 29: 2466-2472.
21. Foukas LC, Berenjeno IM, Gray A, Khwaja A, Vanhaesebroeck B. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci U S A 2010; 107: 11381-11386.
22. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010; 11: 329-341.
23. Prasad NK, Tandon M, Badve S, Snyder PW, Nakshatri H. Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Carcinogenesis 2008; 29: 25-34.
24. Gupta A, Dey CS. PTEN and SHIP2 regulates PI3K/Akt pathway through focal adhesion kinase. Mol Cell Endocrinol 2009; 309: 55-62.
25. Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, DePinho RA, Panayotatos N, Cobb MH, Yancopoulos GD. ERKs: a family of proteinserine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991; 65: 663-675.
26. Fuhler GM, Brooks R, Toms B, Iyer S, Gengo EA, Park MY, Gumbleton M, Viernes DR, Chisholm JD, Kerr WG. Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer. Mol Med 2012; 18: 65-75.
27. Suwa A, Kurama T, Shimokawa T. SHIP2 and its involvement in various diseases. Expert Opin Ther Targets 2010; 14: 727-737.